Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
- , Stephen Begbie
- , Mark Frydenberg
- , Louise Nott
- , Zulfiquer Otty
- , Francis X. Parnis
- , David Pook
- , Shahneen Sandhu
- , Sanjeev Sewak
- , Amanda Stevanovic
- , Martin Stockler
- , Aneta Suder
- , Hsiang Tan
- , Javier Torres
- , Simon Troon
- , Craig Underhill
- , Andrew Weickhardt
- , Robert R. Zielinski
- , Tahir Abbas
- , Ghadeer Anan
Research output: Contribution to journal › Article › peer-review
204
Citations
(Scopus)